The FDA's drug approvals database lists a supplement, dated 14 October, to the biologics licence for Enbrel (etanercept). The entry does not state what changed; such supplements usually cover labelling, manufacturing or presentation.
Etanercept is a TNF inhibitor used in rheumatology and dermatology. It is not used to treat inflammatory bowel disease, unlike infliximab and adalimumab, so this notice has no direct bearing on gastroenterology practice.
- No change to gastroenterology prescribing follows from this notice.
- Remember that etanercept is not a treatment option for Crohn disease or ulcerative colitis.
- Consider new bowel symptoms in patients on etanercept for other conditions on their merits, including possible new-onset IBD.
Why it matters
It is listed for completeness of the regulatory record, not because it alters care.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for gastroenterology & hepatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free